Hosoda K, et al. - A phase 2 study was conducted to assess the effectiveness and safety of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 (DCS) with the intention of finding a new treatment modality that improves prognosis in patients with gastric cancer with bulky node metastasis, linitis plastica (type 4), or large ulcero-invasive-type tumors (type 3). For this investigation, patients received up to four 28-day cycles of DCS therapy (docetaxel at 40 mg/m², cisplatin at 60 mg/m²on day 1, and S-1 at 40 mg/m² twice daily for 2 weeks) followed by gastrectomy with D2 nodal dissection. The percentage of complete resections of the primary tumor with clear margins (R0 resection) was the primary endpoint. Leukocytopenia (27.5%), neutropenia (55.0%), and hyponatremia (22.5%) were the most common grade 3 or 4 adverse events during DCS therapy. The present data indicated that neoadjuvant chemotherapy with DCS was viable and displayed a satisfactory R0 resection rate of 90% in this analysis.